Summary

Other Scenarios:

Buyer: MedImmune, Inc. (MEDI) Last Price: 35.76 Market Cap.: 8.83B
Target: Acambis plc (ADR) (ACAM) Last Price: 7.21 Market Cap.: 3.87B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
*Healthcare 860
Biopharmaceuticals 311
Dermatology   6
Phase I/Phase II Clinical Stage Products   0
Digestive System   5
Research/Preclinical Stage Products   0
Immunology   10
Phase I/Phase II Clinical Stage Products   0
Research/Preclinical Stage Products   0
Infectious Diseases 33
Bacterial   5
Mycological (Fungal)   0
Phase I/Phase II Clinical Stage Products 0
Research/Preclinical Stage Products 0
Viral 8
Musculoskeletal System   3
Research/Preclinical Stage Products   0
Oncology   71
Head/Neck Cancer   0
Phase I/Phase II Clinical Stage Products   0
Research/Preclinical Stage Products   0
Respiratory System/Thoracic   0
Urology   1
Respiratory System   6
Phase I/Phase II Clinical Stage Products   0
Transplantation   0
Heart   0
Hepatic (Liver)   0
Lung   0
Pancreas   0
Renal (Kidney)   0

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 30)
  • CytoGam (Cytomegalovirus Immune Globulin Intravenous)
  • RespiGam (Respiratory Syncytial Virus Immune Globulin Intravenous)
  • Numax (Anti-RSV MAb)
  • Synagis (Palivizumab)
Target (Total: 9)
  • ChimeriVax
  • Vaccinia Immune Globulin (VIG)
  • Smallpox-ACAM2000
  • Arilvax
Buyer
  • MEDI-507 (Siplizumab)
  • HMGB1
  • MDX-1103 (Human Antibodies)
  • MDX-1333 (Human Antibodies)
Target
  • Berna Products Vivotif (Typhoid Vaccine Live Oral Ty21a)
  • Smallpox-MVA3000
  • C. difficile Vaccine
  • ChimeriVax

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 15)
  • Critical Therapeutics, Inc. (CRTX)
  • PDL BioPharma Inc. (PDLI)
  • Cardinal Health, Inc. (CAH)
  • Baxter International Inc. (BAX)
Target (Total: 2)
  • Baxter International Inc. (BAX)
  • Cangene Corporation
Buyer (Total: 7)
  • AmerisourceBergen Corp. (ABC)
  • McKesson Corporation (MCK)
  • Cardinal Health, Inc. (CAH)
  • Caremark Rx, Inc. (CMX)
Target (Total: 1)
  • Federal Government Agencies (United States)

Key Financial Summary:

Metric Buyer Target
Number of Employees 1,976 270
Revenue Per Employee 311,155.5 117,943.6
Total Revenue 492.0 8.0
Total Expenses 502.9 26.8
Other Revenue 0.0 0.0
Cost of Revenue 140.2 9.4
SG&A Expense 198.9 2.4
Research & Development 116.8 15.0
Other Operating Expense 3.3 0.0
Operating Income -10.9 -18.8
Unusual Income 43.7 0.0
Gross Margin % 71.5 -17.39
Metric Buyer Target
Operating Margin % -2.22 -234.78
Total Assets 2,779.1 229.6
Return on Equity % -5.71 -49.33
Cash+ ST Inv. Per Share 5.97 2.39
Total Debt 506.2 8.7
Curr Portion of LTD/Cap Lease 0.0 0.0
Total Debt to Equity 32.23 5.56
LT Debt to Capital 24.38 5.26
Fwd P/E 87.44 n/a
Fwd P/Rev 6.50 n/a
Book Value 1,570.5 156.6

Individual Company Summary

Focused

Buyer

Focused (): *Healthcare > Biopharmaceuticals > Infectious Diseases > Viral

Target

Focused (): *Healthcare > Biopharmaceuticals > Infectious Diseases > Viral > Vaccines

Business Description

Buyer

MedImmune, Inc. is a biotechnology company focusing its efforts on the areas of infectious disease, oncology and immunology. MedImmune markets four products: Synagis (palivizumab) and FluMist (Influenza Virus Vaccine Live, Intranasal) to help prevent two common respiratory infectious diseases; Ethyol (amifostine) to help reduce undesired side effects of certain anti-cancer, chemo and radiotherapies, and Cytogam (cytomegalovirus immune globulin intravenous (human)) to help prevent cytomegalovirus (CMV) disease associated with solid organ transplantation. MedImmune operates facilities in the United States and Europe to manufacture and distribute one or more components of each of its products. MedImmune also has clinical, research and development staff in the United States, through which it is developing a pipeline of product candidates for potential commercialization.

Target

Acambis plc is a biopharmaceutical company operating in the infectious disease arena, with a focus on developing new vaccines. The Company's revenues are principally derived by sales of ACAM2000, the investigational product in its smallpox vaccine franchise, which is being sold to governments, even while it undergoes clinical testing. In addition, revenues also come from sales in North America of an oral typhoid vaccine, Vivotif by its sales and distribution operation, Berna Products Corporation. The majority of Acambis' operations are in the United States, with research and development in Cambridge, Massachusetts; manufacturing in Canton, Massachusetts; a sales and marketing operation in Miami, Florida, and a lyophilisation and fill and finish facility in Rockville, Maryland that the Company acquired in May 2005. During the year ended December 31, 2004, Acambis' customer, the United States Centres for Disease Control and Prevention, accounted for 84% of its revenues.

Product Summary

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
  
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
  
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
  
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
  
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
  
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
  
Transplantation
The Transplantation Subsectors includes therapeutics that treat rejection and infection associated with tissue transplantation into the human body.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Dermatology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • MEDI-507 (Siplizumab)
  
Digestive System  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • HMGB1
  
Immunology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • MEDI-507 (Siplizumab)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • MDX-1103 (Human Antibodies)
  • MDX-1333 (Human Antibodies)
  • MEDI-545 (Human Antibodies)
  • MEDI-507 (Siplizumab)
  • HMGB1
  • Anti-TIRC-7 MAb
  • Anti-Chitinase MAb
  
Infectious Diseases
Bacterial  
Vaccines  
Bacterial  
Single Target  
Typhoid Fever
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause typhoid fever.

Target Products:

  • Berna Products Vivotif (Typhoid Vaccine Live Oral Ty21a)
  
Mycological (Fungal)  
Antifungal Agents  
Narrow Spectrum  
Respiratory System  
Pneumocystis Carinii Pneumonia (PCP)  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat infections of the lungs of immunocompromised patients caused by Pneumocystis carinii by blocking the action of dihydrofolate reductase.

Buyer Products:

  • Neutrexin (Trimetrexate Glucuronate)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.

Buyer Products:

  • Staphylococcal Antibodies Vaccine
  • Anti-Human Metapneumovirus/Parainfluenzavirus Type 3 Vaccine
  • Streptococcus pneumoniae Vaccine
  • RSV Vaccine
  • Numax (Anti-RSV MAb)
  • Escherichia coli Vaccine (FimH Adhesin)
  • Epstein-Barr Virus Vaccine
  • Cytomegalovirus (CMV) Vaccine

Target Products:

  • Smallpox-MVA3000
  • C. difficile Vaccine
  • ChimeriVax
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.

Buyer Products:

  • HMGB1
  • Anti-Human Metapneumovirus Antibodies
  • Streptococcus pneumoniae Vaccine

Target Products:

  • Hyperimmune Globulin
  • Influenza Vaccine Program
Viral
DNA Viruses  
Herpesvirus  
Cytomegalovirus (CMV)  
Immunoglobulins
Therapeutics that treat viral infections characterized by viral inclusion bodies in the nucleus of infected cells with target specific proteins that neutralize the virus.

Buyer Products:

  • CytoGam (Cytomegalovirus Immune Globulin Intravenous)
  
RNA Viruses  
Paramyxovirus  
Respiratory Syncytial Virus (RSV)  
Immunoglobulins
Therapeutics that treat viral infections in the respiratory tracts of infants with a variety of specific protein that neutralizes the virus.

Buyer Products:

  • RespiGam (Respiratory Syncytial Virus Immune Globulin Intravenous)
  
Monoclonal Antibodies
Therapeutics that treat viral infections in the respiratory tracts of infants with a neutralizing protein that targets a specific site on the virus.

Buyer Products:

  • Numax (Anti-RSV MAb)
  • Synagis (Palivizumab)
  • Liquid Synagis (Palivizumab)
  
Vaccines
Viral
Single Target
Influenza (Flu)
Therapeutics that prevent or treat viral infections of the respiratory tract by producing or artificially increasing immunity to the Influenza virus.

Buyer Products:

  • FluMist (Influenza Virus Vaccine Live, Intranasal)
  • Cold Adapted Influenza Vaccine-Trivalent (CAIV-T)
  
Japanese Encephalitis
Therapeutics that prevent or treat viral infections characterized by inflammation of the brain by producing or artificially increasing immunity to the Japanese B Encephalitis virus.

Target Products:

  • ChimeriVax
  
Variola (Smallpox)
Therapeutics that prevent or treat viral infections that cause a diffuse and extensive distribution of lesions by producing or artificially increasing immunity to the Variola virus.

Target Products:

  • Vaccinia Immune Globulin (VIG)
  • Smallpox-ACAM2000
  
Yellow Fever
Therapeutics that prevent or treat viral infections characterized by fever and hemorrhage by producing or artificially increasing immunity to the yellow fever virus.

Target Products:

  • Arilvax
  
Musculoskeletal System  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • HMGB1
  • MEDI-507 (Siplizumab)
  
Oncology  
Head/Neck Cancer  
Palliative Agents  
Thiophosphate Cytoprotective Agents
Therapeutics that treat nephropathy associated with repeated cisplatin treament for head and neck cancers.

Buyer Products:

  • Ethyol (Amifostine)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Buyer Products:

  • MT103
  • Ethyol (Amifostine)
  • MEDI-507 (Siplizumab)
  • Vitaxin (Anti-Alfa-V Beta-3 Antibody)
  • Human Papillomavirus (HPV) Vaccine
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.

Buyer Products:

  • MT103
  • MEDI-507 (Siplizumab)
  • EphA4 Agonists
  • EphA2 Antagonists
  • Anti-Chitinase MAb
  
Respiratory System/Thoracic  
Lung Cancer  
Non Small Cell Lung Cancer (NSCLC)  
Palliative Agents  
Thiophosphate Cytoprotective Agents
Therapeutics that treat nephropathy associated with repeated cisplatin treatment for cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma

Buyer Products:

  • Ethyol (Amifostine)
  
Urology  
Ovarian Cancer  
Palliative Agents  
Thiophosphate Cytoprotective Agents
Therapeutics that treat nephropathy associated with repeated cisplatin treatment for cancers of the ovaries.

Buyer Products:

  • Ethyol (Amifostine)
  
Respiratory System  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • MEDI-528 (IL-9 Monoclonal Antibody)
  
Transplantation  
Heart  
Complications  
Cytomegalovirus (CMV) Infections  
Immunoglobulins
Protein-based therapeutics that treat specific infections.

Buyer Products:

  • CytoGam (Cytomegalovirus Immune Globulin Intravenous)
  
Hepatic (Liver)  
Complications  
Cytomegalovirus (CMV) Infections  
Immunoglobulins
Protein-based therapeutics that treat specific infections.

Buyer Products:

  • CytoGam (Cytomegalovirus Immune Globulin Intravenous)
  
Lung  
Complications  
Cytomegalovirus (CMV) Infections  
Immunoglobulins
Protein-based therapeutics that treat specific infections.

Buyer Products:

  • CytoGam (Cytomegalovirus Immune Globulin Intravenous)
  
Pancreas  
Complications  
Cytomegalovirus (CMV) Infections  
Immunoglobulins
Protein-based therapeutics that treat specific infections.

Buyer Products:

  • CytoGam (Cytomegalovirus Immune Globulin Intravenous)
  
Renal (Kidney)  
Complications  
Cytomegalovirus (CMV) Infections  
Immunoglobulins
Protein-based therapeutics that treat specific infections.

Buyer Products:

  • CytoGam (Cytomegalovirus Immune Globulin Intravenous)
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  GlaxoSmithKline plc (ADR) n/a 158,330.716 19.29 18.56 4.17 4.17 28.38
sanofi-aventis (ADR) n/a 117,145.313 n/a 11.83 4.03 3.33 n/a
Merck & Co., Inc. n/a 76,007.326 16.54 14.81 3.45 3.62 n/a
Chiron Corporation n/a 8,548.136 45.11 24.20 4.45 3.95 2.86
Vical Incorporated n/a 140.636 n/a -5.52 11.72 8.54 1.75
DOR BioPharma, Inc. n/a 21.763 n/a n/a 6.80 n/a 14.74
Buyer
  Pfizer Inc. n/a 191,895.175 23.84 13.03 3.74 3.73 13.64
Johnson & Johnson n/a 175,639.871 16.93 15.76 3.48 3.26 n/a
GlaxoSmithKline plc (ADR) n/a 158,330.716 19.29 18.56 4.17 4.17 28.38
Roche Holding Ltd. (ADR) n/a 131,799.556 29.24 28.64 4.77 n/a 7.51
Target
  GlaxoSmithKline plc (ADR) n/a 158,330.716 19.29 18.56 4.17 4.17 28.38
sanofi-aventis (ADR) n/a 117,145.313 n/a 11.83 4.03 3.33 n/a
Merck & Co., Inc. n/a 76,007.326 16.54 14.81 3.45 3.62 n/a
Wyeth n/a 65,725.563 17.91 16.16 3.50 3.26 8.34
Baxter International Inc. n/a 24,830.452 25.75 18.74 2.52 2.41 11.02
Solvay SA (ADR) n/a 9,363.535 10.18 n/a 0.96 n/a 2.62
Chiron Corporation n/a 8,548.136 45.11 24.20 4.45 3.95 2.86
Crucell N.V. (ADR) n/a 1,009.493 n/a -33.30 21.91 19.66 6.10
VaxGen, Inc. n/a 334.554 n/a -5.37 23.40 7.53 12.55
Oscient Pharmaceuticals Corporation n/a 147.874 n/a -2.06 8.78 3.14 -1.76
AVANT Immunotherapeutics, Inc. n/a 143.873 n/a n/a 29.58 14.59 7.81
Vical Incorporated n/a 140.636 n/a -5.52 11.72 8.54 1.75
SIGA Technologies, Inc. n/a 25.441 n/a -9.50 3.59 2.81 56.28
DOR BioPharma, Inc. n/a 21.763 n/a n/a 6.80 n/a 14.74
Berna Biotech AG n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Baxter International Inc. n/a 24,830.452 25.75 18.74 2.52 2.41 11.02
Buyer
  Critical Therapeutics, Inc. 100.00% 191.111 n/a -3.95 30.71 8.93 2.65
PDL BioPharma Inc. 30.00% 3,572.413 n/a 77.38 12.90 8.68 n/a
Cardinal Health, Inc. n/a 30,604.114 26.61 23.09 0.39 0.37 8.34
Baxter International Inc. n/a 24,830.452 25.75 18.74 2.52 2.41 11.02
Becton, Dickinson and Co. n/a 15,552.519 21.14 19.52 2.81 2.70 5.72
Human Genome Sciences n/a 1,763.817 n/a -6.90 87.23 79.13 n/a
Medarex, Inc. n/a 1,503.267 n/a -8.85 35.23 36.79 9.35
Seattle Genetics, Inc. n/a 225.035 n/a -6.02 23.07 21.38 2.98
Dyax Corp. n/a 209.890 n/a -6.13 10.57 10.95 n/a
Cerus Corporation n/a 204.162 16.65 -8.30 8.38 7.67 5.79
Applix, Inc. n/a 101.035 14.81 17.89 2.73 2.39 5.01
Genaera Corporation n/a 93.405 n/a -2.57 216.11 96.15 2.75
Avalon Pharmaceuticals, Inc. n/a 44.970 n/a -3.38 29.53 7.51 11.97
Purdue University n/a n/a n/a n/a n/a n/a n/a
Panacea Pharmaceuticals, Inc. n/a n/a n/a n/a n/a n/a n/a
Target
  Baxter International Inc. n/a 24,830.452 25.75 18.74 2.52 2.41 11.02
Cangene Corporation n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  AmerisourceBergen Corp. 25.00% 9,564.722 31.53 22.55 0.17 0.17 5.14
McKesson Corporation 18.00% 16,494.123 20.57 22.56 0.19 0.18 4.17
Cardinal Health, Inc. 15.00% 30,604.114 26.61 23.09 0.39 0.37 8.34
Caremark Rx, Inc. 6.00% 21,922.015 23.66 21.63 0.66 0.62 68.89
Medco Health Solutions Inc. n/a 18,047.382 28.25 22.75 0.48 0.43 -106.35
GTC Biotherapeutics, Inc. n/a 53.053 n/a n/a 7.89 3.46 2.64
Curative Health Services, Inc. n/a 2.083 n/a n/a 0.01 0.01 -0.01
Target
  Federal Government Agencies (United States) 84.00% n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Baxter International Inc. n/a 24,830.452 25.75 18.74 2.52 2.41 11.02
Chiron Corporation n/a 8,548.136 45.11 24.20 4.45 3.95 2.86
Buyer
  GlaxoSmithKline plc (ADR) n/a 158,330.716 19.29 18.56 4.17 4.17 28.38
Genentech, Inc. n/a 86,090.809 67.38 47.24 12.98 10.00 15.43
Merck & Co., Inc. n/a 76,007.326 16.54 14.81 3.45 3.62 n/a
Abbott Laboratories n/a 67,576.455 20.20 16.94 3.03 3.03 15.17
Cardinal Health, Inc. n/a 30,604.114 26.61 23.09 0.39 0.37 8.34
Schering-Plough Corp. n/a 26,704.540 145.95 33.33 2.81 2.66 3.92
Baxter International Inc. n/a 24,830.452 25.75 18.74 2.52 2.41 11.02
Teva Pharmaceutical Industries Ltd (ADR) n/a 24,716.755 23.00 20.97 4.71 3.22 8.43
Medco Health Solutions Inc. n/a 18,047.382 28.25 22.75 0.48 0.43 -106.35
Becton, Dickinson and Co. n/a 15,552.519 21.14 19.52 2.81 2.70 5.72
Chiron Corporation n/a 8,548.136 45.11 24.20 4.45 3.95 2.86
Human Genome Sciences n/a 1,763.817 n/a -6.90 87.23 79.13 n/a
Medarex, Inc. n/a 1,503.267 n/a -8.85 35.23 36.79 9.35
Crucell N.V. (ADR) n/a 1,009.493 n/a -33.30 21.91 19.66 6.10
Biosite Incorporated n/a 896.481 16.33 24.33 3.12 2.84 2.89
Tercica, Inc. n/a 238.954 n/a -4.78 n/a 21.21 n/a
Seattle Genetics, Inc. n/a 225.035 n/a -6.02 23.07 21.38 2.98
Dyax Corp. n/a 209.890 n/a -6.13 10.57 10.95 n/a
Target
  sanofi-aventis (ADR) n/a 117,145.313 n/a 11.83 4.03 3.33 n/a
Baxter International Inc. n/a 24,830.452 25.75 18.74 2.52 2.41 11.02
Chiron Corporation n/a 8,548.136 45.11 24.20 4.45 3.95 2.86
Cangene Corporation n/a n/a n/a n/a n/a n/a n/a
Berna Biotech AG n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 1,243.9 69.8 1,313.7
Other Revenue 0.0 0.0 0.0
Total Revenue 1,243.9 69.8 1,313.7
Cost of Revenue 336.7 43.7 380.4
SG&A Expense 494.5 11.3 505.8
Depreciation & Amortization 3.9 0.0 3.9
Research & Development 384.5 53.4 437.9
Interest Expense 0.0 0.0 0.0
Other Operating Expense 12.6 0.0 12.6
Unusual Expense (Income) 48.4 0.0 48.4
Total Expenses 1,280.6 108.4 1,389.0
Operating Income -36.7 -38.6 -75.3
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng 52.3 0.9 53.2
Other, Net 0.0 0.0 0.0
Income Before Taxes 7.5 -32.4 -24.9
Income Taxes 24.1 -5.6 18.5
Income After Taxes -16.6 -26.8 -43.4
Net Income - Excl. Xord. Items -16.6 -26.8 -43.4
Net Income - Incl. Xord. Items -16.6 -26.8 -43.4
Income Avail. to Common -16.6 -26.8 -43.4
Share Items
Basic Avg. Shares Outstanding 246.4 53.6 300.0
Basic EPS - Excl. Xord. Items -0.07 -0.25 -0.14
Basic EPS - Incl. Xord. Items -0.07 -0.50 -0.14
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 246.4 53.6 300.0
F.D. EPS - Excl. Xord. Items -0.08 -0.52 -0.14
F.D. EPS - Incl. Xord. Items -0.08 -0.52 -0.14
Balance Sheet
Assets
Cash and Equivalents 1,471.9 103.6 1,575.5
ST Investments 0.0 24.4 24.4
Accounts Receivable 284.3 24.9 309.2
Inventory 68.5 6.4 74.9
Other Current Assets 0.0 0.0 0.0
Current Assets 1,824.7 159.3 1,984.0
Accum D&A 0.0 0.0 0.0
PPE, Net 381.4 36.2 417.6
Goodwill & Intangibles 334.5 34.1 368.6
Other Assets 0.0 0.0 0.0
Other LT Assets 238.5 0.0 238.5
Total Assets 2,779.1 229.6 3,008.7
Liabilities
Accounts Payable 37.0 60.0 97.0
Payable/Accrued 0.0 0.0 0.0
Accrued Expenses 334.2 0.0 334.2
ST Debt 0.0 0.0 0.0
Other (Current) Liabilities 331.2 0.0 331.2
Current Liab. 702.4 60.0 762.4
LT Debt 506.2 8.7 514.9
Total LT Debt 506.2 8.7 514.9
Deferred Taxes 0.0 2.8 2.8
Other LT Liab. 0.0 1.4 1.4
Total Liabilities 1,208.6 72.9 1,281.5
Shareholders Equity
Common Stock 0.0 18.6 18.6
Additional Paid in Capital 0.0 170.6 170.6
Retained Earnings 0.0 -32.5 -32.5
Other Equity 1,570.5 0.0 1,570.5
Total Equity 1,570.5 156.6 1,727.1
Total Liab. & Equity 2,779.1 229.6 3,008.7
Shares Outstanding 247.0 53.6 300.6
Cash Flow
Operating Cash Flow
CF Net Income n/a -32.4 -32.4
CF Depreciation n/a 7.5 7.5
CF Deferred Taxes n/a 0.0 0.0
Other Non-Cash Items n/a 1.0 1.0
Change in Working Capital n/a -40.2 -40.2
Total Cash From Operating Activities n/a -64.1 -64.1
Investing Cash Flow
Capital Expenditures n/a -7.1 -7.1
Other Investing Cash Flows n/a -2.8 -2.8
Total Cash From Investing Activities n/a -9.9 -9.9
Financing Cash Flow
Dividends Paid n/a 0.0 0.0
Purchase Or Sale of Stock n/a 2.3 2.3
Purchase and Retirement of Debt n/a 118.2 118.2
Other Financing Cash Flow n/a -45.1 -45.1
Total Cash From Financing Activities n/a 69.6 69.6
Exchange Rate Effects n/a 0.0 0.0
Net Change in Cash n/a -4.4 -4.4
Cash Taxes Paid n/a 9.9 9.9
Cash Interest Paid n/a 6.8 6.8